1990
A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy
Roberts R, Hollinger F, Parks W, Rasheed S, Laurence J, Heseltine P, Makuch R, Lubina J, Johnson K, Group R. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy. AIDS 1990, 4: 67-72. PMID: 1690551, DOI: 10.1097/00002030-199001000-00009.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAIDS-Related ComplexDouble-Blind MethodFemaleGene Products, gagHIVHIV AntigensHIV Core Protein p24HIV InfectionsHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesRNA-Directed DNA PolymeraseUnited StatesViral Core ProteinsConceptsOral ribavirinPeripheral blood mononuclear cellsPlacebo-controlled trialBlood mononuclear cellsMulticenter clinical trialHIV isolationP24 antigenemiaStudy drugMulticenter trialActive treatmentDaily dosesMononuclear cellsClinical trialsMedical CenterWeek 6HIV activityAdult menRibavirinTrialsLymphadenopathyHIVInterlaboratory variationCritical roleAntigenemiaPlacebo
1982
Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: Implications for the relationship between African and American Burkitt's lymphoma
Freeman C, Magrath I, Benjamin D, Makuch R, Douglass E, Santaella M. Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: Implications for the relationship between African and American Burkitt's lymphoma. Clinical Immunology 1982, 25: 103-113. PMID: 7151335, DOI: 10.1016/0090-1229(82)90169-6.Peer-Reviewed Original ResearchConceptsEBV nuclear antigenEpstein-Barr virus receptorUndifferentiated lymphomaComplement receptorsExpression of complementEBNA-positive cell linesCell linesVirus receptorAmerican Burkitt's lymphomaCell typesEBV receptorBurkitt's typeReceptor expressionBurkitt's lymphomaNeoplastic counterpartsLymphomaHigh levelsIndividual tumorsVirus producersDegree of expressionNuclear antigenLow levelsReceptorsTumorsEBVExperience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer.
Minna J, Bunn P, Carney D, Cohen M, Cuttita F, Fosieck B, Gazdar A, Ihde D, Johnston-Early A, Matthews M, Makuch R, Oie H, Rosen S, Lichter A, Glatstein E. Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bulletin Du Cancer 1982, 69: 83-93. PMID: 6280795.Peer-Reviewed Original Research
1981
Influence of prognostic factors on survival in Ewing's sarcoma.
Glaubiger D, Makuch R, Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. National Cancer Institute Monograph 1981, 285-8. PMID: 7300894.Peer-Reviewed Original ResearchConceptsPrimary diseaseEwing's sarcomaTreatment groupsSerum lactate dehydrogenase levelIntensive adjuvant chemotherapySystemic chemotherapy regimensLactate dehydrogenase levelsNumber of patientsSignificant differencesNational Cancer InstituteRecent treatment regimensAdjuvant chemotherapyChemotherapy regimensPrognostic factorsPrimary lesionTreatment regimensLDH levelsMetastatic statusSurvival resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer InstituteSarcomaPrimary site
1979
Justification for the lognormal distribution as a model for blood pressure
Makuch R, Freeman D, Johnson M. Justification for the lognormal distribution as a model for blood pressure. Journal Of Clinical Epidemiology 1979, 32: 245-250. PMID: 429469, DOI: 10.1016/0021-9681(79)90070-5.Peer-Reviewed Original Research